Navigation Links
Amgen to Present at the 28th Annual JP Morgan Healthcare Conference
Date:1/16/2010

THOUSAND OAKS, Calif., Jan. 7 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) will present at the 28th Annual JP Morgan Global Healthcare Conference at 8:00 a.m. Pacific Time on Tuesday, Jan. 12, 2010, at the Westin St. Francis in San Francisco, Calif. Amgen Chairman and CEO Kevin Sharer will present at the conference. Live audio of the presentation will be available over the Internet and can be accessed from Amgen's Web site, www.amgen.com, under Investors.

Information regarding presentation time, webcast availability, and webcast links are available on Amgen's Investor Relations Events Calendar.

About Amgen

Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.com.


    CONTACT: Amgen, Thousand Oaks
    David Polk, 805-447-4613 or 805-490-0661 (media)
    Arvind Sood, 805-447-1060 (investors)

(Logo: http://www.newscom.com/cgi-bin/prnh/20081015/AMGENLOGO)

SOURCE Amgen

RELATED LINKS
http://www.amgen.com

'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R)
2. Medarex to Receive Milestone Payment from Amgen
3. AMT Obtains License to Amgens GDNF Gene to Develop Treatment for Parkinsons Disease with AMTs Proprietary Gene Therapy Platform
4. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
5. CDC Foundation Partners with Amgen, CDC to Reduce Infections Among Cancer Patients
6. Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)
7. Amgen Issues Statement on Outcomes of Advisory Committee for Reproductive Health Drugs (ACRHD) Meeting
8. Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes
9. Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP
10. Amgen Highlights Data to be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting
11. Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... 2017 Neurim Pharmaceuticals ("Neurim") and ... exclusive marketing rights for Neurim,s new Rx PedPRM in ... ... sleep disorders in children with Autism Spectrum Disorders (ASD) and neurogenetic ... for children. The collaboration with Exeltis will help increase ...
(Date:3/29/2017)... Research and Markets has announced the addition of the ... report to their offering. ... The global patient safety and risk management software ... geography. Patient safety has become a priority for ... developed significantly in the last decade and is currently on the ...
(Date:3/28/2017)... Md. , March 28, 2017 ... Dupixent (dupilumab) injection to treat adults with moderate-to-severe ... whose eczema is not controlled adequately by topical ... not advisable. Dupixent can be used with or ... Dupixent demonstrates our commitment to approving new and ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... ... Immunotherapy has emerged as one of the most promising options for the ... next revolution in our fight against this complex disease. One of the most effective ... such as PD-1 and PD-L1 inhibitors. , While a few single analyte immunohistochemistry tests ...
(Date:3/29/2017)... PA (PRWEB) , ... March 29, 2017 , ... The ... W’80, WG’81, and Julie Taffet Moelis, W’81, have made a $10 million gift to ... deferred admission opportunity that will provide a pathway to a Wharton MBA for highly-qualified ...
(Date:3/28/2017)... , ... March 28, 2017 , ... Tuesday, March 28, ... American public to take the Diabetes Risk Test to find out if they are ... Angeles World Airports will light up the evening sky by programming the LAX pylons ...
(Date:3/28/2017)... ... 28, 2017 , ... Resoundant, Inc., the developer of ... Healthineers annual customer education symposium, a world-class learning conference that offers educational content ... - 31, 2017 at the Atlanta Marriott Marquis in Atlanta, Georgia. , Innovations ...
(Date:3/28/2017)... Seattle, WA (PRWEB) , ... March 28, 2017 ... ... reach a 22% share of all holidays (IBT World Travel Trends Report). As ... physically challenging, include a range in temperatures, and prolonged sun exposure. In response, ...
Breaking Medicine News(10 mins):